Nanobioconjugate Trispecific Antibody Augments Antitumor Immunity of Triple Negative Breast Cancer Authors: Qing Chang, Linlin Liu Published: 2026 ABSTRACT AbstractIntroductionTriple-negative breast cancer (TNBC) is characterized as the most unfavorable prognosis of the breast cancer subtype. Chemotherapy is currently the primary treatment owing to a persistent lack of effective alternative medicine. To fulfill this unaddressed clinical requirement, we utilized the PGLU-Fc-III-4C MsAb platform to develop a nanobioconjugate trispecific antibody (TsAb; CD3×CD137×CD276) that targeted CD3, CD137, and CD276, aiming to restrict the growth of TNBC tumors (4T1 model) and provide a novel therapeutic strategy.MethodsThe capacity for binding to target cells and anti-tumor effects of TsAb in vitro were evaluated. In vivo antitumor efficacy and biosafety were further assessed in the 4T1 subcutaneous tumor model. Anti-tumor immune responses induced by TsAb on tumor-infiltrating CD8+ T cells were monitored.ResultsThe TsAb effectively bound and facilitated interactions between 4T1 tumor cells and T cells, significantly boosting the anti-tumor effect. TsAb promoted the expansion of tumor and splenic T lymphocytes and facilitated the recruitment of splenic and blood T lymphocytes to tumor tissues. Compared with the PGLU-Fc-III-4C-IgG treatment group, the TsAb treatment group had varying degrees of increase in CD8+ tissue-resident memory T cells (TRM), central memory T cells (TCM), and terminal effector memory T cells (TEM) in tumor tissues. The TsAb treatment group exhibited a significant increase of PD-1+ CD8+ T cells and TCF1−Tim-3+ CD8+ terminally exhausted T cells in tumor tissues. The safety profile demonstrated no obvious systemic toxicity.DiscussionBriefly, TsAb mediated CD8+ T cell activation, proliferation, and terminal differentiation, accompanied by increasing cytokine production to eliminate the tumor. Meanwhile, no obvious systemic toxicity was observed. In general, the CD3×CD137×CD276 nanobioconjugate trispecific antibody provides a promising immunotherapeutic approach via regulating CD8+ T cell immune response for the treatment of triple-negative breast cancer.Keywords: triple-negative breast cancer, nanomedicine, trispecific antibody, CD8+ T cell Introduction Triple-negative breast cancer (TNBC) is the most aggressive, metastatic, and refractory subtype of breast cancer. In light of low expression of progesterone and estrogen receptors as well as low amplification of ERBB2 (also referred to as “human epidermal growth factor receptor 2” [HER2]), TNBC is unable to respond to endocrine therapy or anti-HER-2 targeted therapy.1 Currently, TNBC is treated with antitumor medicines alone, or combined with radiotherapy or surgery.2–4 TNBC exhibits more heterogeneity compared to other solid tumors, resulting in a bleak prognosis, increased risk of relapse, and low progression-free survival and overall survival. The search for more effective therapies is urgent. Due to its high microsatellite instability and mutation burden, TNBC exhibits increased neoantigen production, making it easily recognized by T cells.5,6 This suggests that TNBC may respond to immunotherapy. Owing to achievements in histology and bioinformatics analysis technology, cancer research is evolving towards studying larger samples, utilizing multi-omics techniques, and attempting to achieve greater precision.6–8 The era of high-dose chemotherapy has entered into the era of targeted immunotherapy that is guiding effector immune cells to target and kill tumor cells. Immune checkpoint blocking therapy can block the inhibitory signal of T cell activation to promote an anti-tumor immune response.9,10 Nevertheless, TNBC patients exhibit limited or no response to Immune checkpoint inhibitors (ICIs), owing to relatively low infiltration of cytotoxic T lymphocytes and a low PD-L1 expression rate in TNBC estimated at around 20%.11,12 A phase III clinical trial for advanced TNBC patients treated with a combination of atezolizumab and paclitaxel did not improve overall survival.13 Various targeted therapeutic approaches have been developed based on the distinct molecules and signaling pathways of TNBC.14 CD276 is an immune checkpoint molecule belonging to the B7 superfamily.15,16 It has been identified in tumor cells, tumor vascular endothelial cells, and professional antigen presentation cells (APCs).17 CD276 has been extensively studied for its role in tumor growth and immune evasion. Blocking CD276 increases T-cell infiltration, which is advantageous to other strategies based on T-cell-driven anti-tumor immune responses.18,19 The overexpression of CD276 in TNBC patient tumor tissues was major in more than 60–80%, and minimal to low expression levels were observed in normal organs.20,21 Therefore, B7-H3 represents a promising biomarker and therapeutic target for TNBC immunotherapies. T cells are the primary cells of the immune system that eliminate tumor cells. T cell activation relies on signal integration and the attainment of an activation threshold.22 In the solid tumor microenvironment, T cells commonly display an elevated activation threshold, and engagement of the TCR-CD3 signaling alone is frequently insufficient to trigger complete T-cell activation.23 Correspondingly, targeted immunotherapy strategies are at the forefront of research efforts.24–26 T cell immunotherapy utilizes the distinct features of anti-tumor T cells to augment their effectiveness in eradicating tumor cells. Immune checkpoint inhibitors, multispecific antibodies, and adoptive cell treatments are the mainstays mentioned.27–31 T cell engagers (TCEs) are compounds that can bind to two or more different epitopes or antigens at the same time, which simultaneously bind CD3 or co-stimulatory molecules on T cells and tumor-associated antigens on tumor cells to redirect cytotoxic T cell activity.32,33 They can then direct T cells towards tumor cells or relieve their depression, enhancing the specific killing effect on tumor cells. As a classical co-stimulatory receptor, CD137 can amplify the activation signal and further exert potent and long-term immune effects.34,35 A wide range of TCEs are in preclinical and clinical development stages. The primary reasons for treatment failure include rapid clearance of TCEs in vivo and life-threatening systemic toxicities such as cytokine release syndrome (CRS), and complex manufacturing processes also restrict their clinical applicability.36,37 Our research group presented a facile and versatile nanoplatform for MsAbs, a polymer grafted with multiple Fc-binding peptides.38 To prepare such complexes, simply mix the desired antibody with the carrier in an aqueous solution without purification. Our study utilized the PGLU-Fc-III-4C MsAb platform to generate a CD3/CD137/CD276 nanobioconjugate trispecific antibody (TsAb), which bound CD3 and CD137 on T cells and CD276 on tumor cells for synergistic antitumor activity. We investigated its mechanism of inhibiting TNBC growth and increasing its anticancer efficacy, aiming to provide a theoretical basis and feasible strategies for TNBC treatment. As a proof of concept, the CD3/CD137/CD276 nanobioconjugate TsAb not only demonstrates a new targeted strategy in developing TNBC therapeutic nanomedicine but also may provide a reference for broadly applicable platform technology for next-generation immunotherapies. Materials and Methods Cell Lines and Culture Conditions The murine TNBC cell line, 4T1, was procured from Pricella (Wuhan, China). Cultivation of 4T1 cells was carried out in RPMI 1640 medium augmented with 10% fetal bovine serum (FBS), 1% penicillin, and 1% streptomycin. Incubation of the cells was performed at 37°C with 5% CO2 in a sterile, humidified incubator. Mice Female BALB/c mice (6–8 weeks old) were purchased from Beijing Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China) and raised under specific pathogen-free conditions in conformity to the approved protocols of the Animal Care and Use Committee of Changchun Institute of Applied Chemistry (20220048). The mice were acclimatized in the facility for at least one week before the commencement of any experimental procedures, with randomly grouping and rigorous measures taken to mitigate any potential suffering during experimentation. At the end of the experiment, mice were anesthetized using isoflurane inhalation until complete loss of reflexes was confirmed, followed by cervical dislocation to ensure death. The mice carcasses were stored in the designated freezer. No tumor exceeded the maximum allowable volume of 2 cm3 in the study. Synthesis of PGLU-Fc-III-4C and PGLU-Fc-III-4C-Abs PGLU (16.07 mg, 0.8 µmol) and N,N′-disuccinimidyl carbonate (13.83 mg, 0.05 mmol) were dissolved in 5 mL DMF, and then mixed with triethylamine (9.36 mg, 0.09 mmol) in an anhydrous environment. The mixture was incubated at 37 °C for 48 hours before adding Fc-III-4C (20 mg, 0.01 mmol) and additional triethylamine (4.68 mg, 0.05 mmol). After 12 more hours at 37 °C, the solution was dialyzed against DMF and PBS, and freeze-dried. The antibodies and PGLU-Fc-III-4C were mixed at a mass ratio of 15.38:1 and incubated in phosphate-buffered saline (PBS, 0.01 M, pH 7.4) at 4 °C for 1 hour to yield PGLU-Fc-III-4C-Abs. The antibodies of TsAb were at an αCD3 (BioXcell, BE0001): αCD137 (BioXcell, BE0239): αCD276 (BioXcell, BE0124) mass ratio of 1:1:1. Characterization of PGLU-Fc-III-4C and PGLU-Fc-III-4C-Abs The chemical structures of PGLU-Fc-III-4C were analyzed using 1H nuclear magnetic resonance spectroscopy (Bruker) with NaOD/D2O as the solvent. Size measurements were conducted using a Zetasizer Nano ZS (Malvern). Imaging was performed with a field emission scanning electron microscope (FESEM microscope, Zeiss). Isolation of Primary T Cells Primary CD8+ T cells were extracted from 8–10-week-old female BALB/c mice. Splenocytes were obtained by harvesting spleens from healthy 8–10-week-old mice. The isolation of primary CD8+ T cells from mouse spleens was accomplished using an immunomagnetic negative selection method employing the EasySepTM Mouse CD8+ T Cell Isolation Kit (Stemcell Technologies, 19853), following the manufacturer’s instructions. Subsequently, the isolated primary CD8+ T cells were cultured in complete RPMI 1640 medium supplemented with DynabeadTM Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activation (Gibco, 11456D). Prior to being utilized for in vitro experiments, CD8+ T cells were incubated in complete media for 24 hours. Association Between Cells and TsAb A total of 5×104 4T1 cells and 1.5×105 CD8+ T cells were seeded in 12-well plates and incubated overnight. PGLU-Fc-III-4C labeled with cyanine 2 was prepared for PGLU-Fc-III-4C-IgG and TsAb as previously described. PGLU-Fc-III-4C-IgG or TsAb was added and co-cultured with cells for 15 h. The concentration of total antibodies was 15 μg/mL. The samples were prepared in PBS with 2% FBS and examined by a BD FACS Celesta flow cytometer. A total of 5×104 4T1 cells and 1.5×105 CD8+ T cells were seeded on glass coverslips and incubated overnight. PGLU-Fc-III-4C-IgG or TsAb was added and co-cultured with cells for 15 h. The concentration of total antibodies was 15 μg/mL. The sample was fixed with 2.5% glutaraldehyde for 1 hour at room temperature and washed 3×5 min with water before dehydration and sputter coating. Imaging was done on a Zeiss FESEM Merlin microscope. Samples were fixed with 2.5% glutaraldehyde for 1 hour at room temperature, followed by 3×5 min water washes, ethanol gradient dehydration, and sputter coating. Imaging was performed using a Zeiss FESEM Merlin microscope. In vitro Cytotoxicity Assays A total of 5×103 4T1 cells and 1.5×104 CD8+ T cells were seeded in 96-well plates and cultured overnight. PGLU-Fc-III-4C-IgG, free mixed antibodies (αCD3e+α4-1BB+αCD276), or TsAb was added into the wells and were co-cultured with cells for 30 h. The concentration of total antibodies was 15 μg/mL. Antibodies of free mixed antibodies were at an αCD3: αCD137: αCD276 mass ratio of 1:1:1. Post-treatment, cells were analyzed by CCK-8 assays according to the manufacturer’s instructions. Cytokine ELISA In vitro, a total of 1×104 4T1 cells and 3×104 CD8+ T cells were seeded in 48-well plates and cultured overnight. PGLU-Fc-III-4C-IgG, αCD3e antibody, α4-1BB antibody, αCD276 antibody, free mixed antibodies (αCD3e+α4-1BB+αCD276), or TsAb were added into the wells and were co-cultured with cells for 30 h. For αCD3e antibody, α4-1BB antibody, or αCD276 antibody, the concentration of antibodies was 5 μg/mL. For PGLU-Fc-III-4C-IgG, free mixed antibodies, or TsAb, the concentration of total antibodies was 15 μg/mL. Antibodies of free mixed antibodies were at an αCD3: αCD137: αCD276 mass ratio of 1:1:1. Post-treatment, IFN-γ, perforin, and granzyme B levels in cell supernatants were measured using ELISA kits (Invitrogen and Anoric), according to the manufacturer’s instructions. In vivo experiments, blood and tissue (tumor and spleen) were harvested from mice after the end of (3A) treatment and subjected to grinding and centrifugation to obtain a homogenate supernatant (n = 4 per group). Cytokine (IL-2, IL-6, granzyme B, perforin, IFN-γ, and TNF-α) levels were measured using mouse ELISA kits (Invitrogen and Anoric). Accumulation of TsAb and ex vivo Imaging PGLU-Fc-III-4C was labeled with cyanine 5 and prepared for PGLU-Fc-III-4C-IgG and TsAb following a previously described method. 4T1 cells were subcutaneously implanted into the 6-week-old female BALB/c mice. When tumor volume reached about 100 mm3, mice were randomly allocated to different treatment groups (n = 4 per group) and intratumorally injected once with cyanine 5-labeled PGLU-Fc-III-4C-IgG (0.8 mg kg–1) and TsAb (0.8 mg kg–1). Thirty hours after intratumoral injection, tumor tissue and spleen were prepared and imaged using an IVIS Lumina LT Seres III in vivo imaging system (PerkinElmer), which were then analyzed using Living Image software. The tumor/spleen ratio was calculated by dividing the values of the identified region of interest. Flow Cytometry 4T1 cells were subcutaneously implanted into the 6-week-old female BALB/c mice. When tumor volume reached about 100 mm3, mice were randomly allocated to different treatment groups (n = 4 per group) and intratumorally injected on day 0 and day 1 (once a day) with PGLU-Fc-III-4C-IgG (0.8 mg kg–1), TsAb (0.32 mg kg–1) and TsAb (0.8 mg kg–1). Blood and tissue (tumor and spleen) were collected on day 2 and prepared into single cells for analyzing T cell composition and changes in the population. Cell suspensions were prepared in PBS containing 2% FBS to maintain a density of 1–5 million cells/mL. Fixation, permeabilization, and antibody staining were subsequently performed according to the experimental design. Antibodies were used according to the manufacturer’s protocol for flow cytometry analysis. Samples were examined by a BD FACS Celesta flow cytometer. All the FACS data were analyzed with FlowJo software. Gating strategies were shown in Figure S10. Therapeutic Studies Subcutaneous injections of 4T1 breast cancer cells (5 × 105 cells) were administered into the flanks of syngeneic female BALB/c mice (~20 g; aged 6–8 weeks). After ten days following the implantation of the tumor, therapy was initiated. On day 14, the mice were sacrificed. The tumors were measured every alternate day using a vernier caliper. The tumor volume (Vt) was calculated as per the following formula: a×b2/2, where a is the longest dimension and b is the shortest dimension. For the 4T1 breast cancer model with a low dose of TsAb treatment, mice were randomly allocated to different treatment groups (n = 6 per group), and each animal was intratumorally injected on two consecutive days and discontinued on the following two days (4 days as one cycle, a total of 4 cycles) with the vehicle (for the control group), PGLU-Fc-III-4C (0.02 mg kg–1), αCD3e antibody (0.1 mg kg–1), α4-1BB antibody (0.1 mg kg–1), αCD276 antibody (0.1 mg kg–1), MTAb (0.3 mg kg–1), or TsAb (0.32 mg kg–1). For the 4T1 breast cancer model with a high dose of TsAb treatment (n = 6 per group), each animal was intratumorally injected on two consecutive days and discontinued on the following two days (4 days as one cycle, a total of 4 cycles) with the vehicle (for the control group), PGLU-Fc-III-4C-IgG (0.8 mg kg–1), a low dose of TsAb (0.32 mg kg–1), or a high dose of TsAb (0.8 mg kg–1). Toxicity Studies Body weight during (2A) treatment was regularly measured to assess gross toxicity (n = 6 per group). Tissues (tumor, heart, liver, spleen, lung, and kidney) after the end of (2A) treatment were sectioned and stained with hematoxylin and eosin (H&E). For the desired time, mice were bled and sacrificed. Blood was collected from a mouse fully anesthetized after the end of (2A) treatment (n = 4 per group). Mouse plasma was obtained by centrifugation and stored at −80°C until analysis. The analysis of plasma levels of BUN, UA, CRE, AKP, ALT, and AST was performed by the Nanjing Jiancheng Bioengineering Institute (Nanjing, China). 4T1 cells were subcutaneously implanted into the 6-week-old female BALB/c mice. When tumor volume reached about 100 mm3, mice were randomly allocated to different treatment groups (n = 4 per group) and intratumorally injected on day 0 and day 1 (once a day) with vehicle (for the control group), PGLU-Fc-III-4C-IgG (0.8 mg kg–1), MTAb (0.3 mg kg–1), TsAb (0.32 mg kg–1) and TsAb (0.8 mg kg–1). Mouse plasma was collected on day 2 using the method described above and stored at −80°C until analysis. The analysis of plasma levels of BUN, UA, CRE, AKP, ALT, and AST was performed by the Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Hematoxylin and Eosin (H&E) Staining When BALB/c mice bearing 4T1 breast cancer were sacrificed, the tumors and major organs (heart, liver, spleen, lung, and kidney) were isolated and fixed in 4% paraformaldehyde immediately. Then samples were embedded in paraffin and sectioned. After tissue sections were stained with hematoxylin and eosin (H&E), histological alterations were taken by a microscope (Olympus). Immunohistochemistry Immunohistochemical staining was conducted via the two-step immunocytochemistry protocol. Tumor samples were fixed with 4% paraformaldehyde, embedded in paraffin, and sectioned. All sections were subjected to antigen retrieval and blocking of nonspecific binding. Sections were then incubated with anti-CD8 antibody (Biolegend, 100701) followed by horseradish peroxidase-conjugated IgG secondary antibody. After thorough washing, the samples were stained using DAB and counterstained with hematoxylin. Microscopic observation (Olympus) was used to generate images, and quantitative analyses were performed using ImageJ software (NIH). Statistical Analysis Two-tailed unpaired t tests were performed for comparison between the two groups. A one-way ANOVA with Tukey post-hoc tests were carried out to compare multiple groups. P < 0.05 was considered statistically significant. The statistical significance was defined as: n.s. = not significant, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001. Data are shown as mean ± SD. All statistical analyses were calculated using GraphPad Prism. Results Functional Characterization of TsAb We developed TsAb following the steps shown in Figure 1A and characterized it (Figures S1–3). PGLU and Fc-III-4C reacted at 37 °C in an anhydrous environment. It was calculated that the grafting number of Fc-III-4C in PGLU-Fc-III-4C was 5.17 based on the 1H NMR spectrum. The antibodies and PGLU-Fc-III-4C were incubated in PBS at 4 °C for 1 hour to yield nanobioconjugate TsAb. DLS results showed that all antibodies were binding to PGLU-Fc-III-4C without the need for purification. Prepare the TsAb solution fresh and use, and verify consistency by DLS. The capacity for TsAb binding to target cells was evaluated. Compared to the PGLU-Fc-III-4C-IgG, the conjugate formations of TsAb and targeted cells were more prevalent in the 4T1, T, and co-culture systems (43%, 49%, and 32%, respectively) (Figure 1B). The SEM analysis (Figure 1C) showed few T cells attached to 4T1 cells following treatment with PGLU-Fc-III-4C-IgG. The cells exhibited flat, irregularly polygonal shapes and displayed a normal growth morphology. Nevertheless, the TsAb group exhibited an average of 3.33 T cells adhered to each 4T1 cell, while 4T1 cells shrank, turned smaller, and became less tightly bound. These results demonstrated that the nanobioconjugate trispecific antibody effectively bound and facilitated interactions between 4T1 tumor cells and T cells. To evaluate the in vitro anti-tumor effects of TsAb-induced T cell-mediated cytotoxicity, we measured cell viability and cytokine levels with the CCK8 and ELISA assays. Figure 1E revealed that TsAb treatment at various concentrations showed enhanced tumor inhibition over a mixture of three antibodies (CD3 & CD137 & CD276, MTAb) after 30 hours. Moreover, dose-dependent cytotoxicity of TsAb facilitated T cell-tumor cell interactions, reducing 4T1 cell viability to 12.9% at 15000 ng/mL. The TsAb group secreted more IFN-γ, granzyme B, and perforin than the MTAb group, indicating higher T cell activation with TsAb (Figure 1D). The in vitro experiments showed that TsAb significantly boosted anti-tumor immunity. Functional characterization of TsAb. (A) The acquisition of nanobioconjugate TsAb. Signals at δ 4.23 ppm (a), δ 1.93 ppm (b, g), δ 2.23 ppm (c, j), δ 3.05 ppm (d), δ 1.16 ppm (e), δ 0.74 ppm (f) and δ 6.75–7.56 ppm (h, i), were respectively assigned to hydrogens in the Figure S1. (B) The Capacity of TsAb to bind targeted cells. FACS data are presented as means ± s.d. (n = 3 biologically independent samples) (C) The representative SEM images of TsAb binding and facilitating interactions between 4T1 tumor cells and T cells. (scale bar –10 μm) (D) The levels of IFN-γ, granzyme B, and perforin in the supernatant of the coincubation system were examined using ELISAs. Data are presented as means ± s.d. (n = 3 biologically independent samples) (E) Viability of 4T1 cells in the coincubation system at various concentrations of TsAb. Data are presented as means ± s.d. (n = 3 biologically independent samples) (F) Ex vivo bioluminescence images of tumor and spleen at 30h after the i.t. injection of Cy5-labeled TsAb. (i.t.: intratumoral injection) n.s.no significance; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. The in vivo drug response of the PGLU-Fc-III-4C-IgG, MTAb, and TsAb was assessed by locally injecting them into tumor-bearing mice and subsequently monitoring the tumor, spleen, and overall condition of the mice. As depicted in Figure S4, no significant alterations in tumor size were observed in the group treated with PGLU-Fc-III-4C-IgG 24 hours post-injection; furthermore, their general condition remained satisfactory. The mice in the MTAb-treated group exhibited tumor shrinkage and had the abnormal behaviors of retardation, irritability, piloerection, stiffness of tail etc. They succumbed to death within 3 days after injection. In contrast, the mice in the TsAb-treated group also showed tumor shrinkage while their behavior was relatively normal. These results indicated that TsAb exhibited lower toxicity while demonstrating therapeutic effects on tumors. Furthermore, Cy5-labeled PGLU-Fc-III-4C-IgG and TsAb were injected into mice bearing tumors, and fluorescence imaging was conducted 30 hours later using harvested tumor and spleen tissues. As depicted in Figure 1F, there was no significant difference observed in the average fluorescence intensity of tumors between the PGLU-Fc-III-4C-IgG group [(2.85 ± 0.29) *107 (p/s/cm2/sr)/(µW/cm2)] and the TsAb-treated group [(2.82 ± 0.58) *107 (p/s/cm2/sr)/(µW/cm2)] (Figure S5A). This suggested that PGLU-Fc-III-4C-Abs possesses certain metabolic stability within tumors, possibly due to non-specific accumulation caused by the enhanced permeability and retention effect (EPR). Notably, strong signals were detected in spleens from the TsAb-treated group, which indicated increased localization within this organ with a spleen/tumor ratio of (69.6 ± 12.59)%, significantly higher than that observed in the PGLU-Fc-III-4C-IgG-treated group (45.18 ± 9.32)% (Figure S5B and C). This phenomenon of partial accumulation in spleens might be attributed to active targeting capabilities of TsAb towards this organ after systemic circulation entry. Enhancing Anti-Tumor Efficacy with TsAb To further elucidate the in vivo therapeutic efficacy of TsAb against TNBC, treatment was initiated in tumor-bearing mice when the tumor volume reached approximately 50 mm3. The progression of tumors and survival period of the mice were observed, with specific dosages and treatment times outlined in Figure 2A. As illustrated in Figure 2B and Figure S6, both the MTAb and TsAb treatment groups exhibited therapeutic benefits compared to the control group. MTAb slightly inhibited tumor growth (P < 0.05), while TsAb exerted a notably higher antitumor effect than that of the MTAb-treated group (P < 0.05). Tumor weight measurements after dissection (Figure 2C) revealed a tumor inhibition rate of 55.66% in the TsAb-treated group, with tumor weight (0.41 ± 0.09 g) significantly lower than that in the PBS group (0.93 ± 0.09 g, P < 0.0001), PGLU-Fc-III-4C group (0.97 ± 0.09 g, P < 0.0001), and MTAb-treated group (0.61 ± 0.13 g, P < 0.01). Histological examination of tumor sections stained with hematoxylin and eosin (HE) (Figure 2E) revealed that the control group exhibited densely packed tumor cells with large nuclei, high nuclear-cytoplasmic ratios, and frequent mitotic figures. In contrast, the MTAb and TsAb treatment groups showed sparser cell arrangements, necrosis, and nuclear fragmentation. Additionally, both MTAb and TsAb treatments improved the average survival time of tumor-bearing mice compared to the control group (Figure 2D). The survival curve for the TsAb-treated group shifted notably to the right, with a median survival time extended to 25 days. It was suggested that TsAb-treated group had significantly higher survival rates and longer survival periods compared to the MTAb-treated group (P < 0.05). In summary, TsAb treatment not only inhibited tumor growth but also effectively prolonged the survival time of tumor-bearing mice. In vivo anti-tumor efficacy with TsAb (0.32mg/kg). (A) The experimental scheme with specific dosages and treatment times. (i.t.: intratumoral injection) (B) The average tumor growth curves of 4T1 tumors in mice treated with different formulations. Data are presented as means ± s.d. (n = 6 mice per group). (C) Tumor weights after different treatments. Data are presented as means ± s.d. (n = 6 mice per group) (D) Survival curves for each group of mice. (n = 6 mice per group) (E) The representative images of H&E staining of tumors after the end of (A) treatment. (scale bar –100 μm) *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. To enhance the therapeutic efficacy of TsAb, mice were treated with low-dose TsAb and high-dose TsAb when the tumor volume reached approximately 50 mm3. The progression of tumors were observed, with specific dosages and treatment times outlined in Figure 3A. As depicted in Figure 3B and Figure S7, both low-dose and high-dose TsAb treatment groups exhibited significant therapeutic benefits compared to the control group (P < 0.0001), while the high-dose TsAb treatment group showed significantly greater tumor inhibition effects than the low-dose TsAb treatment group (P < 0.01). Tumor weight measurements after dissection (Figure 3C) revealed that the tumor weight in the high-dose TsAb treatment group (0.24 ± 0.06 g) was significantly lower than that in the PBS group (1.16 ± 0.07 g, P < 0.0001), PGLU-Fc-III-4C-IgG group (1.03 ± 0.1 g, P < 0.0001), and low-dose TsAb treatment group (0.48 ± 0.17 g, P < 0.01). The tumor inhibition rate in the high-dose TsAb treatment group was 79.45%, significantly higher than that in the low-dose TsAb treatment group (58.68%)(Figure 3D). Histological examination of tumor sections stained with HE (Figure 3E) revealed that the high-dose TsAb treatment group showed increased tumor cell death, which indicated that the efficacy of TsAb against TNBC tumors exhibited a dose-dependent effect. In vivo anti-tumor efficacy with TsAb (0.8mg/kg). (A) The experimental scheme with specific dosages and treatment times. (i.t.: intratumoral injection) (B) The average tumor growth curves of 4T1 tumors in mice treated with different formulations. Data are presented as means ± s.d. (n = 6 mice per group). (C) Tumor images and weights after different treatments. Data are presented as means ± s.d. (n = 6 mice per group) (D) The tumor inhibition rates of the low-dose and high-dose TsAb treatment group. (n = 6 mice per group) (E) The representative images of H&E staining of tumors after the end of (A) treatment. (scale bar –100 μm) *P < 0.05; **P < 0.01; ****P < 0.0001. Anti-Tumor Immune Responses Induced by TsAb To further monitor the immune effects of TsAb on tumor-infiltrating CD8+ T cells, tumor tissues were isolated after the last treatment for immunohistochemical analysis and cytokine detection. Compared to the control group, the TsAb-treated group exhibited increased infiltration of CD8+ T lymphocytes (Figure 4A), along with significant increases in the levels of IL-2, TNF-α, IFN-γ, granzyme B, and perforin (Figure 4B). Additionally, the level of IL-2 in the spleen was significantly increased in the TsAb-treated group (Figure S8). These results indicated that the TsAb promoted the infiltration and proliferation of T cells in tumors and enhanced anti-tumor immune responses. IL-6 is a key cytokine in CRS.39 The level of plasma IL-6 significantly increased in the MTAb-treated group, while there was no significant change in the TsAb-treated group (Figure S9). The finding confirmed that no obvious CRS were triggered under TsAb treatment. The cytotoxicity of TsAb against tumors relies on the redirection and activation of T cells.40,41 To further monitor the effects of TsAb on T cells and their subsets, flow cytometric analysis was conducted on the second day of treatment. Compared to the PGLU-Fc-III-4C-IgG-treated group, the low-dose TsAb treatment group exhibited a significant increase of tumor-infiltrating T lymphocytes (P < 0.01), a slight increase of splenic T lymphocytes, and a significant decrease in blood T lymphocytes (P < 0.05) (Figure 4C). The high-dose TsAb treatment group showed even higher levels of tumor T cell infiltration (P < 0.001) and splenic T cell expansion (P = 0.08). These results indicated that TsAb promoted the expansion of tumor and splenic T lymphocytes and facilitated the recruitment of splenic and blood T lymphocytes to tumor tissues. Tumor-specific T cells are the main effector cells of the anti-tumor immune response, which can persist and provide protection upon antigen re-exposure.42–45 Their functions are restricted in the tumor microenvironment. Compared with the PGLU-Fc-III-4C-IgG treatment group, the TsAb treatment group had varying degrees of increase in CD8+ tissue-resident memory T cells (TRM), central memory T cells (TCM), and terminal effector memory T cells (TEM) in tumor tissues (Figure 4D). These results indicated that TsAb promoted the anti-tumor effect of T cells and drove the expansion of tumor-specific memory T cells. In tumors, continuous antigenic stimulation can lead to T cell exhaustion. CD8+ T cells typically reach an exhausted state through effector memory T cells or tissue-resident memory T cells.46–48 The terminally differentiated cells can act as short-lived cytotoxic effector cells to exert anti-tumor effects. Compared with the PGLU-Fc-III-4C-IgG treatment group, the TsAb treatment group exhibited a significantly increase of PD-1+ CD8+ T cells and TCF1− Tim-3+ CD8+ terminally exhausted T cells in tumor tissues (Figure 4E). These results indicated that TsAb targets tumor-specific T cells and enhanced their terminal differentiation capacity. TsAb promotes the infiltration of CD8 T cells and anti-tumor immune responses in vivo. (A) The representative immunohistochemical images of CD8 in tumors after the end of (3A) treatment. (scale bar – 50 μm) (B) The levels of IL-2, TNF-α, IFN-γ, granzyme B, and perforin in tumors were examined after the end of (3A) treatment using ELISAs. Data are presented as means ± s.d. (n = 4 biologically independent samples) (C) The percentage of CD8+ T cells in the tumor, spleen, and blood on the second day of treatment. Data are presented as means ± s.d. (n = 4 biologically independent samples) (D) The percentage of CD8+ TEM, TCM, and TRM cells in tumors on the second day of treatment. Data are presented as means ± s.d. (n = 4 biologically independent samples) (E) The percentage of CD8+ PD1+ exhausted T cells in tumors on the second day of treatment. Data are presented as means ± s.d. (n = 4 biologically independent samples) *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Absence of Systemic Adverse Events Following TsAb Treatment To further clarify the systemic toxicity of TsAb treatment, changes in body weight of tumor-bearing mice were recorded during the antitumor experiment. Plasma was isolated after the first cycle of treatment and at the end of the last treatment for blood biochemical analysis. Additionally, organs such as the heart, liver, spleen, lungs, and kidneys were isolated after the final treatment for H&E staining of paraffin sections to assess organ histopathological changes. During the treatment period, the body weight of mice in the MTAb-treated group remained lower than that of the control group, while the body weight of mice in the TsAb-treated group decreased after the first cycle of treatment and recovered to normal level during the treatment hiatus (Figure 5A). At the end of the last treatment, there were no significant differences in body weight among the groups compared to the control group. The H&E staining results (Figure 5B) showed that compared to the control group and the TsAb-treated group, mice in the MTAb-treated group exhibited significant hepatocyte swelling, pale cytoplasm, centrally located nuclei, and balloon-like changes. The morphologies of other organ cells were normal, and no obvious pathological changes were observed. BUN, UA, CRE, AKP, ALT, and AST levels were analyzed after the end of treatment (Figure 5C) and the first cycle of treatment (Figure 5D). Compared to the control group (9.79 ± 2.74 U/L), the MTAb-treated group exhibited elevated alanine aminotransferase (ALT) levels after the first cycle of treatment (34.21 ± 20.27 U/L, P < 0.05), which were significantly higher than those in the TsAb-treated group (10.28 ± 5.4 U/L, P < 0.05). At the end of the last treatment, ALT levels in the MTAb-treated group (32.15 ± 11.59 U/L) remained elevated, with significant differences compared to the control group (8.84 ± 4.07 U/L, P < 0.001) and the TsAb-treated group (11.05 ± 5.53 U/L, P < 0.01). Furthermore, compared to the control group (48.09 ± 13.87 U/L), the MTAb-treated group (126.74 ± 11.2 U/L, P < 0.001) exhibited increased aspartate aminotransferase (AST) levels at the end of the last treatment, significantly higher than those in the low-dose TsAb-treated group (62.93 ± 24.3 U/L, P < 0.01). Blood urea nitrogen (BUN), uric acid (UA), creatinine (CRE), and alkaline phosphatase (AKP) levels were not significantly elevated in any treatment group. These results indicated that TsAb caused no obvious acute and chronic organ damage or irreversible toxicity. Observation of side effects following TsAb treatment. (A) The changes in body weight of mice after the end of (2A) treatment. Data are presented as means ± s.d. (n = 6 mice per group) (B) Representative images of H&E staining of major organs after the end of (2A) treatment. (scale bar –100 μm) (C) BUN, UA, CRE, AKP, ALT, and AST levels after the end of (2A) treatment. Data are presented as means ± s.d. (n = 4 biologically independent samples) (D) BUN, UA, CRE, AKP, ALT, and AST levels on the second day of treatment. Data are presented as means ± s.d. (n = 4 biologically independent samples) n.s.no significance; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Discussion Significant progress has been made in understanding the complex immune evasion mechanisms of TNBC.49–51 The highly fibrotic, overly connective tissue hyperplasia and a viscous extracellular matrix (ECM) in TNBC naturally constitute a particularly dense physical barrier.52 Disordered structure and function of the vascular wall in the TNBC microenvironment also greatly hinder the penetrability of macromolecules.53 Intratumoral injection represents a significant direction for TNBC local therapy owing to the accessibility of superficial tumors, which achieves a non-inferior therapeutic effect with significant reduction of toxicity compared to the systemic administration.54 T cells serve as the primary effector cells of the immune system in killing tumor cells. The anti-tumor response is determined by the unique T cell receptor and the specificity of antigen presentation by the major histocompatibility complex molecules (MHC).55,56 Targeted strategies related to T cells are a hot topic of concern for researchers.57–59 However, most of these therapy strategies still have many imperfections.60,61 They usually have low response rates or need to go through weeks of individual preparation process. As an alternative, TCEs can simultaneously achieve a variety of mechanisms of action, such as activating immune cells or blocking immune checkpoints while locating cancer cells.62 This process prolongs the effect time of immune cells, increases their intensity, and enhances the anti-tumor effect. The complex manufacturing processes and rapid clearance in vivo of conventional TCEs restrict their clinical applicability. Here, we present an alternative TsAb, the CD3/CD137/CD276-targeted TsAb (T cell engagement + co-stimulation + tumor targeting), which is a nanobioconjugate trispecific antibody based on PGLU-Fc-III-4C (an Fc-binding peptide-based build platform for MsAbs). To prepare such TsAb, simply mix the desired antibody with the carrier in an aqueous solution without purification. The TsAb demonstrated promising efficacy in inhibiting tumor growth and improving survival rates in mice models of TNBC, presenting its potential as a novel therapeutic approach for this aggressive subtype of breast cancer. The ability of TsAb to redirect and activate T cells, as evidenced by increased tumor-infiltrating T lymphocytes and enhanced secretion of pro-inflammatory cytokines, underscored their mechanism of action in eliciting potent anti-tumor immune responses. The safety profile revealed no obvious systemic toxicity. Intratumoral injection not only enhanced the retention and accumulation of TsAb in the tumor but also made it challenging for TsAb to rapidly and extensively enter the systemic circulation, which prevented the occurrence of acute CRS. In addition, most T cells in the solid tumor microenvironment exhibit a higher activation threshold, which makes it difficult to trigger complete CRS.23 Overall, our research confirmed the feasibility and effectiveness of nanobioconjugate trispecific antibody. Future studies should focus on the molecular mechanisms and effects of TsAb treatment on distant tumors and long-term immune memory, including therapeutic efficacy, immune memory effect and potential development of drug resistance. These explorations are conducive to developing treatment strategies and optimizing combination therapies for TNBC. Meanwhile, contributions of TsAb to therapeutic mechanisms and biosafety in splenic immune modulation should be clarified and evaluated. The murine model exhibits distinct biological characteristics compared with human TNBC. Therefore, further stoichiometric optimization of identifying the optimal formulation, comprehensive safety evaluation, and validation in more clinically relevant humanized TNBC models are required to promote the future clinical translation. Additionally, exploration of biomarkers predictive of response to TsAb treatment most likely to benefit from this immunotherapy approach will be crucial for personalized treatment strategies and improving outcomes in TNBC. Acknowledgments This work was supported by Science and Technology Department of Jilin Province (YDZJ202102CXJD020), Development and Reform Commission of Jilin Province (2021C023), and Department of Finance of Jilin Province (2020SCZT035). The authors are grateful to Changchun Institute of Applied Chemistry for offering the PGLU-Fc-III-4C and favorable research conditions during the completion of this study. Disclosure The authors report no conflicts of interest in this work. References